Sygnature Discovery debuts expansion plans for its U.K. campus

CRO Sygnature Discovery unveils plans to expand the footprint of its campus with the addition of a new facility. (Pixabay)

U.K.-based CRO Sygnature Discovery unveiled plans to expand the footprint of its campus with the addition of a new facility.

Sygnature, which provides integrated drug discovery and preclinical services, said the expansion will double its drug metabolism and pharmacokinetics (DMPK) department as part of the firm’s efforts to bolster its recruitment program.

The department is focused on the delivery and interpretation of discovery DMPK data to pharma and biotech organizations. The new facility will be located at the company’s Alderly Park campus.


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

“The demand for our DMPK services and expertise is growing rapidly year on year, so we are expanding the team and bringing in more expertise to meet this growing client need,” Dr. Jonathan Williams, Sygnature’s COO, said in a statement.

As part of the expansion, some DMPK employees will be relocating from Nottingham to Alderly Park.

The DMPK department was launched in 2015 with the appointment of Dr. Tim Schulz-Utermoehl as director. Previously, he worked for Shire.


Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.